{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:21:36Z","timestamp":1761920496518,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Foundation of Fujian Educational Committee","award":["JA15198"],"award-info":[{"award-number":["JA15198"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bcmd.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T15:09:29Z","timestamp":1535641769000},"page":"22-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A novel somatic CALR mutation in essential thrombocythemia and effective response to interferon-alfa-2b therapy"],"prefix":"10.1016","volume":"73","author":[{"given":"Xueya","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qichen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2018.08.004_bb0005","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triplenegative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2018.08.004_bb0010","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2018.08.004_bb0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2018.08.004_bb0020","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.08.004_bb0025","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1038\/bcj.2014.7","article-title":"Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca(2+): some mechanistic and therapeutic implications","volume":"4","author":"Shivarov","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcmd.2018.08.004_bb0030","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.08.004_bb0035","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.23665","article-title":"CALR mutation studies in chronic neutrophilic leukemia","volume":"89","author":"Lasho","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2018.08.004_bb0040","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1182\/blood.V124.21.4588.4588","article-title":"In-frame exon 9 CALR deletions co-occur with other alterations in the JAK-STAT pathway in myeloproliferative neoplasms","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcmd.2018.08.004_bb0045","first-page":"e295","article-title":"Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood","volume":"20","author":"Lim","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.bcmd.2018.08.004_bb0050","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2018.08.004_bb0055","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979618302985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979618302985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:33:15Z","timestamp":1761049995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979618302985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":11,"alternative-id":["S1079979618302985"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2018.08.004","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel somatic CALR mutation in essential thrombocythemia and effective response to interferon-alfa-2b therapy","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}